
A series of biomarker discoveries developed by researchers at Mayo Clinic and the University of Minnesota have resulted in a licensed technology that will benefit prostate cancer patients globally. The research that led to the discoveries and subsequent patents was funded by one of the first grants awarded by the Minnesota Partnership. Mayo Clinic's Eric Wieben, Ph.D., program manager for the Partnership, says, "This is a great example of why the Partnership was created. A relatively small amount of initial support led to larger government grants and a successful outcome in a diagnostic test that will no doubt save lives and improve treatment."
Click here for news release
Cancer affects people worldwide, regardless of age, gender or socioeconomic status. That's why Mayo Clinic joins the Union for International Cancer Control and other global organizations on World Cancer ...
BARRON, Wis. — Preventive health screenings are important for everyone, yet these simple and routine things are not readily available to some. Nothing in life ...
Cancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In the last three ...